HRS-8179

The primary objective is to explore if HRS8179 could improve midline shift at 72 hours (or at time of decompressive craniectomy or comfort measures only, if earlier) in participants with large hemispheric infarction. The secondary objective is to explore if HRS8179 could improve acute neurologic status, functional outcomes, treatment requirements and safety.

1、主要目的：评价在健康受试者中静脉给予HRS8179注射液的安全性和耐受性。 2、次要目的：评价在健康受试者中静脉给予HRS8179注射液的药代动力学特征。